10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

MEF2C (Ser222) Antibody
Rabbit Polyclonal Antibody
Catalog # AN1280

Specification

MEF2C (Ser222) Antibody - Product Information

Application	**WB**
Primary Accession	Q06413
Reactivity	**Human**
Host	**Rabbit**
Clonality	**Polyclonal**
Calculated MW	**51221**

MEF2C (Ser222) Antibody - Additional Information

Gene ID	**4208**
Gene Name	**MEF2C**

Target/Specificity
Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser222 conjugated to KLH

Dilution
WB~~ 1:1000

Format
Antigen Affinity Purified from Pooled Serum

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions
MEF2C (Ser222) Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Shipping
Blue Ice

MEF2C (Ser222) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- Immunohistochemistry
- Immunofluorescence
- Immunoprecipitation

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

- Flow Cytomety
- Cell Culture

MEF2C (Ser222) Antibody - Images



Western blot of OCIAML2 lysate showing specific immunolabeling of the ~51 kDa MEF2C phosphorylated at Ser222 in the first lane (-). Phosphospecificity is shown in the second lane (+) where the immunolabeling is completely eliminated by blot treatment with lambda phosphatase ((λ-Ptase, 1200 units for 30 minutes).

MEF2C (Ser222) Antibody - Background

MEF2C, also known as MADS box transcription enhancer factor 2, polypeptide C, is one of 4 MEF2 (myocyte enhancer factor 2) transcription factors that encode proteins for development of skeletal muscle and brain proliferation and differentiation (McDermott et al, 1993), along with regulating stress-response during cardiac hypertrophy in mammals (Wu et al, 2015). Phosphorylation of MEF2C at serine 59 has been shown to be negatively regulated by integrin-linked kinase (ILK) (Dong et al, 2015). Recently, high MEF2C expression has been associated with a subset of acute myeloid leukemia (AML) patients with adverse-risk disease features and poor outcomes (Laszlo et al, 2015). Phosphorylation of MEF2C at serine 222 may play a key role in MEF2C signaling.